Mobile

A study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures Et tre-ar...

Update Il y a 4 ans
Reference: EUCTR2011-000860-90

A study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures Et tre-armet, randomiseret, dobbeltblindt, placebo-kontrolleret klinisk forsøg til vurdering af effekt og sikkerhed ved to forskellige doser everolimus som supplerende behandling til patienter med Tuberøs Sklerosekompleks med vanskeligt kontrollerbare partielle anfald

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the reduction in frequency of partial-onset seizures on each of two trough ranges of everolimus (3-7 ng/mL and 9-15 ng/mL) versus placebo in patients with TSC who are taking one to three AEDs

Inclusion criteria

  • Refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)

Links